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PHARMACY
Stress Ulcer Prophylaxis
Muhammad Amir, Specialist Clinical Pharmacy
It is general practice to initiate Acid Suppressing Medications (ASM) as Stress ulcer 
prophylaxis (SUP) to reduce the risk of gastrointestinal bleeding (GlB), albeit researches 
shows that SUP is continued for longer period than required. Researches also shows that 
28% of ICU patients receive inappropriate ASM and 81% are inappropriately continued 
on SUP upon transfer from lCU. Recently, two major concerns with respect to ASM has 
been raised. First, an increased risk of C. Difficile and nosocomial infection. Secondly, 
it is found that ASMs do not affect the rate of GI bleed with no risk factors. Sucralfate 
is commonly not been used as SUP due to its increased drug interaction. Proton Pump 
Inhibitors (PPI) and Histamine Receptor Antagonist (H2RA) are commonly used and 
suggested for SUP. No ASMs have been found superior to each other for this indication in 
terms of health outcomes (benefit or adverse) and cost.
To standardized use of ASM in Surgical ICU, guideline is established to ensure 
its appropriate use and discontinuation. Ranitidine is suggested as the first line 
therapy because of its better pharmacokinetic profile and cost minimization value. 
Its pharmacokinetic profile allows a dosing regimen which does not fully suppress 
gastric acid and may limit infection risk. Additionally, Omeprazole interaction with 
QT prolonging drugs is an upcoming concern also. Furthermore, interaction of 
Omeprazole with Clopidogrel can also be avoided. The efficacy of Clopidogrel reduced 
by omeprazole due to inhibition of its metabolism pathway (CYP2C19), hence it was 
suggested that patient prescribed with Clopidogrel should be either be on ranitidine (lV/ 
Oral) or pantoprazole. Details of the guideline can be found in:
http://betaportal.aku.edu/GI-Surgery/Key%20Documents/Policies,%20Procedures,%20Protocols,%20
Clinical%20Practice%20Guideline/Guideline%20for%20Prophylaxis%20for%20Stress%20Ulcer.pdf
Use of Diazoxide in Hypoglycemia due to 
Hyperinsulinism in Neonates 
Gul Ambreen, Senior Pharmacist 
Diazoxide is the drug of choice for the treatment of persistent and severe hypoglycemia 
due to hyperinsulinism in neonates. It is a nondiuretic hypotensive and antihypoglycemic  
agent that is structurally related to the thiazide diuretics. Diazoxide increases blood 
glucose concentration by inhibiting pancreatic insulin secretion, stimulating the release 
of catecholamines and/or increasing the hepatic release of glucose. Diazoxide has a 
marked inhibitory effect on glucose induced insulin secretion.  After oral administration 
of Diazoxide suspension in the doses of 10-15mg/kg/day in two to three divided doses 
with feed. Hyperglycemic effects begin within 1 hour and last approximately 8 hours in 
patients with normal renal function. 1 It reduces peripheral vascular resistance and blood 
pressure as a result of direct vasodilatory effect on smooth muscle in peripheral arterioles. 
Diazoxide causes sodium and water retention and decreased urinary output, which can 
result in expansion of plasma and extracellular fluid volume, edema and congestive 
cardiac failure. Concurrent administration of a diuretic (e.g. hydrochlorathiazide) is 
recommended. 2 
Other Possible Adverse Effects: 3
 1. Hypertrichosis
 2. Neonatal jaundice 
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New Update:  Direct Oral Anti-Coagulants (DOACs)
Kashif Hussain, Specialist Clinical Pharmacy
American College of Cardiology issued a specialist accord archive in December 2017 to help doctors on the management of 
bleeding in patients taking oral anticoagulants. Since normal activated partial thromboplastin time (aPTT) is not useful for 
monitoring new DOACs and these assays are not readily available. Recommendation includes:
1-Dabigatran is reversible with the monoclonal antibody derived antidote, Idarucizumab. The antidote is indicated for severe 
bleeding in patients taking Dabigatran.
2- Andexanet alfa, an antidote to factor Xa, was approved by the FDA in May 2018 with indications for patients with major bleeding 
while taking factor Xa inhibitors Rivaroxaban and Apixaban.
3- Prothrombin complex concentrate has been suggested as a treatment for bleeding due to DOACs other than Dabigatran.
Crossing over anticoagulation with enoxaparin or other low molecular weight heparin drugs in the perioperative period is not 
viewed as essential or prudent for most patients taking DOACs. The medication can essentially be halted for a time of days before 
the surgery.
 3. Gastrointestinal disturbances (nausea and vomiting).
 4. Arrhythmias, tachycardia.
 5. Elevated serum uric acid levels 
 6. Cerebral ischemia/convulsions.
 7. Blood dyscrasias (neutropenia, leukopenia, and thrombocytopenia).
 8. Transient cataracts with prolonged use.
 9. Pulmonary hypertension 
 10. Dilatation of the ductus arteriosus 
Contraindicated in compensatory hypertension with aortic coarctation or AV shunt.                                              
Use with caution in infants with congestive heart failure and renal insufficiency and impaired carbohydrate metabolism. 3
Special Considerations3
 1. Is NOT a drug of choice in treatment of hypertensive emergencies in newborns.
 2. Hypokalemia potentiates the hyperglycemic effect.
 3. Diazoxide causes sodium retention and diuretics may need to be administered concomitantly
Drug Interactions: Concomitant administration with diuretics, anti-hypertensive, and corticosteroids potentiates hyperglycemia 
and hypotension.  Concomitant administration with phenytoin has resulted in both failures to achieve seizure control and phenytoin 
toxicity 1.
Monitoring parameters: 
 1. Monitor glucose levels carefully.
 2. Monitor blood pressure.
 3. Continuous cardiorespiratory monitoring. Observe for arrhythmias.
 4. Monitor fluid balance carefully.
 5. Weigh daily.
 6. CBC 
 7. Uric acid concentration (specially for long-term treatment) 
Antidote: Discontinue Diazoxide; administer insulin as necessary for hyperglycemia; treat hypotension with sympathomimetic 
agents.
References:
 1. Diazoxide: AHFS Detalied Monogrpah. Medscape.
  http://www.medscape.com/druginfo/monograph?cid=med&drugid=10322&drugname=Diazoxide+IV&monotype=monograph. Accessed 
  on 30/07/2007.
 2. Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fekete C, De Lonlay-Debeney P, Brunelle F, Otonkoski T, Thornton P and 
  Lindley KJ. Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000; 82: F98-F107
 3. NeoFax Essentials 2017 
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Most patients can be restarted on their oral anticoagulant 24 hours in the wake of experiencing a medical procedure or system that 
conveys a generally safe of post procedure bleeding. Restarting anticoagulation following 2 to 3 days is prompted for patients at 
higher hazard for bleeding.
For reversal of warfarin, vitamin K is still considered the first-line agent, preferably to be infused by slow intravenous dosing. 
Prothrombin complex concentrates have also been suggested for reversal of serious bleeding associated with warfarin.
References:
 1- Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in   
 Patients on Oral Anticoagulants. J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067. 
Case Study: Use of Cholestyramine for Management Of Digoxin 
Toxicity
Mahreen Muzammil, Clinical Pharmacist, Pharmacy Services 
A female patient came with digoxin toxicity with the levels of  2.9 ng/mL (0.5–2 ng/mL).  It was suggested to add Cholestyramine  
4 gram every six hourly.   Digoxin level was  0.9 ng/mL on next day. 
The effectiveness of  Cholestyramine  have been proven in many studies for toxication of digoxin. Due to Cholestyramine, the 
serum concentration of digoxin reduces rapidly, and its half-life decreases from 75.5 hours to 19.9 hours. All signs and symptoms 
of toxic reaction also subsides during the its period of therapy. Cholestyramine and a related agent, colestipol, presumably interrupt 
the enterohepatic recycling of digoxin to enhance elimination. These agents represent potentially useful adjunctive measures in the 
management of non— life-threatening digitalis intoxication. 1
References:
 1- Henderson, R. P. and C. P. Solomon (1988). “Use of cholestyramine in the treatment of digoxin intoxication.” Archives of internal 
  medicine 148(3): 745-746. 
Updates : Use of Doxycycline in Children
Taniya Zaidi, Pharmacist
Tetracycline are bacteriostatic antibiotics that are used to treat infection caused by many aerobic gram-positive and gram-negative 
bacteria. Doxycycline is one of the most active tetracyclines and is the most often used clinically since it possesses many advantages 
over traditional tetracycline and minocycline. Use of tetracyclines is restricted in children under 8 years of age because of its 
side effect, teeth discoloration. The degree of staining appears to depend on dosage, duration of therapy, and which drug in the 
tetracycline class is used. However, doxycycline binds less readily to calcium than other tetracyclines, and the risk of dental staining 
with short courses of doxycycline is minimal.  In an observational study of 53 children who received approximately two courses of 
doxycycline for Rocky Mountain spotted fever before they were eight years old, none developed dental staining in their permanent 
teeth. Updated recommendations from the American Academy of Pediatrics now permit doxycycline for ≤21 days in children of all 
ages. The dose of doxycycline, as per WHO expert recommendation is 5mg/kg/day in 2 divided doses.
References: 
 American Academy of Pediatrics. Tetracyclines. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin 
 DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.905.
Serotonin Syndrome – Myths & Misconceptions
Hafsah Ashfaq, Clinical Pharmacist
Serotonin syndrome (SS) is an actually life-threatening condition associated with increased serotonergic activity in the central ner-
vous system (CNS). It is seen with therapeutic medication use, unintended interactions between drugs, and deliberate self-poisoning. 
The Hunter criteria is used to diagnose the SS which focus more on the neuromuscular findings of clonus, muscle rigidity, tremor, 
and hyperreflexia—are more reliable for diagnosing SS.
3
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Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
Two common misunderstandings are responsible for the inaccurate listing of various drugs as causes of SS. First, drugs capable 
of producing serotonergic effects differ widely in their possibility of causing SS. Just combining 2 serotonergic drugs does not 
certainly increase the risk for SS. There are different serotonin receptors, and only some of them appear to be involved in the 
etiology of SS. Second, very few drugs (mainly the monoamine oxidase inhibitors) are capable of producing severe SS, while a 
much greater number of drugs can cause mild to moderate SS.
The prevalence of serotonin syndrome is increasing with the expanded use of serotonergic agents and, specifically, with 
polypharmacy.
Treatment includes removal of the causative agents and may also include the use of serotonin antagonists (i.e., cyproheptadine). 
Immediate symptomatic management like hypertension, tachycardia, hyperthermia, and respiratory distress. Usually symptoms 
resolves within 24 hours of discontinuation of causative drugs. Benzodiazepines, such as diazepam or lorazepam, usually used to 
decrease agitation, myoclonus, and muscle rigidity.
Prevention of Serotonin Toxicity 
Complete medication history to be taken in order to identify patients at risk. Prescribers should reconsider the use of two or more 
serotonergic medications and/or consider switching to less-serotonergic alternatives, if appropriate.
Pharmacists should monitor medication regimens for interactions between serotonergic agents and counsel patients. Educating 
patients at risk for potential adverse effects from serotonergic agents (e.g., muscle spasms, confusion, sweating, shaking, shivering) 
should be an essential part of counseling. 
All SSRIs in combination
Venlafaxine And Lithuim
Venlafaxine And Moclobemide
Venlafaxine And Fluoxetine
Venlafaxine And Mirtazapine
Fluoxetine And Sertraline
Fluoxetine And Tramadol
Trazodone And Buspirone
Clomipramine And MAOI
Clomipramine And Trazodone
Clomipramine And Moclobemide
Dextromethorphan And Paroxetine
Dextromethorphan And Moclobemide
Linezolid And Citalopram
SSRIs And St. John’s Wort
SSRIs and MAOI
Meperidine And MAOI
COMBINATIONS THAT MAY RESULT IN SEROTONIN SYNDROME
SSRIs : selective serotonin reuptake inhibitors, MAOI : Monoamino oxidase inhibitors
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